Aimmune Therapeutics Announces Proposed Public Offering of Common Stock

Aimmune currently expects to use the net proceeds from this offering to fund its ongoing clinical development of AR101, an investigational biologic for the treatment of patients with peanut allergy, regulatory activities related to the potential filing of a Biologics License Application and a Marketing Authorization Application for AR101, preparation for potential commercialization of AR101, research and development of additional CODIT^TM product candidates, and for general corporate purposes.

BofA Merrill Lynch, Cantor Fitzgerald & Co. and Piper Jaffray & Co. are acting as joint bookrunning managers for the offering. Credit Suisse and RBC Capital Markets are also acting as bookrunning managers.

A registration statement relating to the securities being sold in this offering was filed with the Securities and Exchange Commission on February 20, 2018, and was automatically declared effective upon filing. The offering of these securities is being made only by means of a prospectus, copies of which may be obtained from: BofA Merrill Lynch, NC1-004-03, 200 North College Street, 3rd floor, Charlotte, NC 28255-0001, Attention: Prospectus Department, email: dg.prospectus_requests@baml.com; or from Cantor Fitzgerald & Co., Attention: Capital Markets, 499 Park Avenue, 6th Floor, New York, NY 10022; email: prospectus@cantor.com; or from Piper Jaffray & Co., Attention: Prospectus Department, 800 Nicollet Mall, J12S03, Minneapolis, MN 55402, via telephone at 800-747-3924 or email at prospectus@pjc.com.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of, these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification of these securities under the securities laws of any such state or jurisdiction.

About Aimmune Therapeutics

Aimmune Therapeutics, Inc., is a clinical-stage biopharmaceutical company developing treatments for potentially life-threatening food allergies. The company’s Characterized Oral Desensitization ImmunoTherapy (CODIT™) approach is intended to achieve meaningful levels of protection by desensitizing patients with defined, precise amounts of key allergens. Aimmune’s first investigational biologic product using CODIT™, AR101 for the treatment of peanut allergy, has received the FDA’s Breakthrough Therapy Designation for the desensitization of peanut-allergic patients 4–17 years of age and is currently being evaluated in Phase 3 clinical trials.

View source version on businesswire.com: http://www.businesswire.com/news/home/20180220006569/en/